These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 8069516)

  • 1. Japanese pharmacopeial perspectives on particle measurement of injections.
    Fujishita O; Sendo T; Otsubo K; Aoyama T
    J Pharm Sci Technol; 1994; 48(3):148-54. PubMed ID: 8069516
    [No Abstract]   [Full Text] [Related]  

  • 2. A new coincidence model for single particle counters, Part I: Theory and experimental verification.
    Knapp JZ; Abramson LR
    J Pharm Sci Technol; 1994; 48(3):110-34. PubMed ID: 8069513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. USP perspectives on particle contamination of injectable products.
    Gallelli JF; Groves MJ
    J Parenter Sci Technol; 1993; 47(6):289-92. PubMed ID: 8120733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of improved standardization methods and instrumentation in the USP particulate test for SVI.
    Barber TA; Lannis MD; Williams JG; Ryan JF
    J Parenter Sci Technol; 1990; 44(4):185-203. PubMed ID: 2213427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carleton's corner. Should the United States pharmacopeia define manufacturing process limits?
    Korczynski MS
    J Parenter Sci Technol; 1991; 45(2):76. PubMed ID: 2051259
    [No Abstract]   [Full Text] [Related]  

  • 6. Particulate-matter content of 11 cephalosporin injections: conformance with USP limits.
    Parkins DA; Taylor AJ
    Am J Hosp Pharm; 1987 May; 44(5):1111-8. PubMed ID: 3605122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. General requirements for parenteral pharmaceuticals for the 21st USP revision--for the 21st Century.
    Barnstein CH
    J Parenter Drug Assoc; 1979; 33(5):287-9. PubMed ID: 259651
    [No Abstract]   [Full Text] [Related]  

  • 8. [Overfill of solid injectable preparations].
    Albertario E; Battelli G; Chiarabaglio G; Mardente S; Minojetti P; Pellegrini M; Romagnoli E; Santoro P; Tassara A; Zitani L
    Boll Chim Farm; 1983 Oct; 122(10):455-61. PubMed ID: 6671032
    [No Abstract]   [Full Text] [Related]  

  • 9. Report on the PQRI impurity characterization and quantification best practices survey.
    Faustino P; Chan CC; Carrano J; Gosnell M; Gu ZQ; Maule A; Sigvardson K; Zhang YF
    Pharm Res; 2006 Feb; 23(2):440-6. PubMed ID: 16477396
    [No Abstract]   [Full Text] [Related]  

  • 10. New quality standards for herbal products.
    Chase SL
    RN; 2000 Mar; 63(3):98. PubMed ID: 10765382
    [No Abstract]   [Full Text] [Related]  

  • 11. Proposed USP microbial limits.
    Agalloco J; Akers J
    J Parenter Sci Technol; 1991; 45(4):168-9. PubMed ID: 1770408
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacopeial harmonization in biotechnology.
    Dabbah R; Grady LT
    Curr Opin Biotechnol; 1998 Jun; 9(3):307-11. PubMed ID: 9687175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Standard particulate sets for visual inspection systems: their preparation, evaluation, and applications.
    Borchert SJ; Maxwell RJ; Davison RL; Aldrich DS
    J Parenter Sci Technol; 1986; 40(6):265-76. PubMed ID: 3819980
    [No Abstract]   [Full Text] [Related]  

  • 14. The pharmacopeial perspective in accelerating the development and availability of biologicals and biotechnological-derived products.
    Williams RL
    Dev Biol (Basel); 2002; 109():137-42. PubMed ID: 12434923
    [No Abstract]   [Full Text] [Related]  

  • 15. International Conference on Harmonisation; Guidance on Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the International Conference on Harmonisation Regions; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Feb; 73(35):9575-6. PubMed ID: 18677819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influencing standard setting.
    Robinson JR
    J Parenter Sci Technol; 1986; 40(3):77. PubMed ID: 3746573
    [No Abstract]   [Full Text] [Related]  

  • 17. Application of the equivalence test for analytical method transfers: testing precision using the United States Pharmacopoeia concept (1010).
    Schepers U; Wätzig H
    J Pharm Biomed Anal; 2006 Apr; 41(1):290-2. PubMed ID: 16338114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a U.S.P. Type I glass for the pharmaceutical industry.
    Abendroth RP
    J Parenter Sci Technol; 1985; 39(3):112-3. PubMed ID: 3998968
    [No Abstract]   [Full Text] [Related]  

  • 19. Letter: Vive la difference.
    Neumeyer JL
    J Pharm Sci; 1976 Jun; 65(6):IV. PubMed ID: 778375
    [No Abstract]   [Full Text] [Related]  

  • 20. Reporting drug defects.
    Belson JJ
    Hosp Formul; 1975 Feb; 10(2):78-9. PubMed ID: 10316674
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.